Article
Biochemistry & Molecular Biology
Valentino Racki, Marina Marcelic, Igor Stimac, Daniela Petric, Natalia Kucic
Summary: This study characterized the effects of haloperidol, risperidone, and aripiprazole on BV-2 microglial cells, revealing that all three antipsychotics successfully reduced the pro-inflammatory actions of the microglial cells, with aripiprazole uniquely increasing the expression of anti-inflammatory markers. The most significant differences in possible mechanisms of action were observed in real-time metabolic assays and mTORC1 signaling pathway activity, with aripiprazole being the only antipsychotic to reduce mTORC1 activity. These results provide new insights into the effects of haloperidol, risperidone, and aripiprazole on microglial cells, suggesting a novel potential mechanism of action for aripiprazole.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Behavioral Sciences
Richard Houghton, Joop van den Bergh, Kiely Law, Yutong Liu, Frank de Vries
Summary: This study compared the risk of bone fractures among 6624 children with autism spectrum disorder (ASD), half of whom used risperidone and half of whom used aripiprazole. Taking other factors into account, risks were similar between the two groups throughout the first 180 days on treatment, but significantly higher in the aripiprazole group thereafter. The biggest differences were in lower leg and ankle fractures. Overall, compared with aripiprazole, risperidone was associated with 40% lower risk of fracture.
Article
Clinical Neurology
Esther Setien-Suero, Victor Ortiz-Garcia de la Foz, Paula Suarez-Pinilla, Benedicto Crespo-Facorro, Rosa Ayesa-Arriola
Summary: The study compared the effects of risperidone and aripiprazole on cognition in patients with first-episode psychosis and found slight differences in their impact on cognitive function. This suggests the need for further research to determine the specific efficacy patterns of these drugs on cognition.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2021)
Article
Medical Laboratory Technology
Minami Tasaki, Norio Yasui-Furukori, Kazuyoshi Kubo, Saaya Yokoyama, Masataka Shinozaki, Norio Sugawara, Yoshimasa Inoue, Kazutaka Shimoda
Summary: The study found that lower prolactin levels are associated with higher plasma drug concentrations in male and female patients with schizophrenia treated with aripiprazole.
THERAPEUTIC DRUG MONITORING
(2021)
Article
Immunology
Hai Duc Nguyen, Won Hee Jo, Ngoc Hong Minh Hoang, Min -Sun Kim
Summary: Cognitive impairment and organic solvent exposure are significant concerns in public health. This study investigated the therapeutic effects of risperidone on cognitive impairment caused by 1,2-diacetylbenzene (DAB) using in vivo and in silico methods. Risperidone was found to alleviate DAB-induced cognitive impairment through various molecular mechanisms, including inhibition of GSK-3β, amyloid-β, CDK5, BACE, and tau hyperphosphorylation. It also suppressed DAB-induced activation of inflammatory pathways and oxidative stress. In silico analyses identified the involvement of prolactin signaling, miRNA regulation, and CEBPB in the pathophysiology of DAB-induced cognitive impairment. These findings suggest the potential use of risperidone in treating cognitive impairment caused by organic solvents, particularly DAB.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Psychiatry
Jingda Cai, Li Li, Tiannan Shao, Mengxi Sun, Weiyan Wang, Peng Xie, Xiaoyi Wang, Ye Yang, Yujun Long, Dongyu Kang, Jingmei Xiao, Yuhan Su, Xingjie Peng, Yuyan Huang, Menghui Gao, Qiongqiong Wu, Chuhan Song, Furu Liu, Ping Shao, Jianjun Ou, Yidong Shen, Jing Huang, Renrong Wu
Summary: Hyperprolactinemia and metabolic disturbance are common side effects of antipsychotics. This study investigated the relationship between antipsychotic switching, baseline clinical status, metabolic changes, and relapse in patients with schizophrenia. The results showed that patients with higher baseline symptoms were more likely to relapse, and switching to aripiprazole increased the risk of relapse regardless of the original medication. Changes in medication also had different effects on metabolic indices in patients with different baseline drugs.
PSYCHIATRY RESEARCH
(2023)
Review
Psychiatry
Milena Stojkovic, Branimir Radmanovic, Mirjana Jovanovic, Vladimir Janjic, Nemanja Muric, Dragana Ignjatovic Ristic
Summary: Risperidone is a commonly used antipsychotic medication known for its safety and efficacy in reducing psychotic symptoms. However, it can lead to non-selective side effects, including hyperprolactinemia, which can impair somatic functions and decrease quality of life. Recognizing and treating risperidone-induced hyperprolactinemia is crucial for improving patient outcomes.
FRONTIERS IN PSYCHIATRY
(2022)
Article
Pharmacology & Pharmacy
Yaowaluck Hongkaew, Andrea Gaedigk, Bob Wilffert, Roger Gaedigk, Wiranpat Kittitharaphan, Nattawat Ngamsamut, Penkhae Limsila, Apichaya Puangpetch, Rattanaporn Sukprasong, Chonlaphat Sukasem
Summary: This study investigated the association between genetic variations in pharmacodynamic genes and risperidone-induced increased prolactin levels in ASD patients. Specific DRD2 diplotypes were found to be related to higher prolactin levels, suggesting a genetic risk score impact on prolactin levels. Additionally, patients who responded to risperidone had lower levels of prolactin.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Agriculture, Dairy & Animal Science
F. Sosa, A. T. Carmickle, L. J. Oliveira, M. Sagheer, M. Saleem, F. H. Yu, M. D. Altman, S. Dikmen, A. C. Denicol, T. S. Sonstegard, C. C. Larson, P. J. Hansen
Summary: This study suggests that the SLICK1 mutation does not alter the abundance of sweat glands in the skin, but it does modify the functional properties of the sweat glands.
JOURNAL OF DAIRY SCIENCE
(2022)
Article
Psychiatry
Wang Zhenhua, Chen Haizhi, Li Jing, Fei Xiaocong, Li Jianhua, Liu Jianjun, Lei Lilei, Jin Haiying
Summary: Risperidone and amisulpride can cause hyperprolactinemia and macroprolactinemia, and detection of MPRL in the clinical setting is important as this phenomenon appears early in treatment (the second week) and continues, which can prevent unnecessary examination and treatment for asymptomatic patients with macroprolactinemia.
ASIA-PACIFIC PSYCHIATRY
(2022)
Article
Pediatrics
Hamza A. Alsayouf, Haitham Talo, Marisa L. Biddappa, Emily de los Reyes
Summary: Research suggests that risperidone and aripiprazole may have positive effects on behavior and core symptoms of ASD in very young children (<4 years), but may also come with side effects such as excessive weight gain.
Article
Agriculture, Dairy & Animal Science
Froylan Sosa, Jose E. P. Santos, D. Owen Rae, Colleen C. Larson, Marissa Macchietto, Juan E. Abrahante, Thiago F. Amaral, Anna C. Denicol, Tad S. Sonstegard, Peter J. Hansen
Summary: The SLICK1 mutation in bovine PRLR results in a phenotype characterized by short hair coat and increased heat stress resistance. The mutation, a dominant allele affecting liver gene expression, can also potentially impact other physiological characteristics. Results suggest that inheritance of the SLICK1 allele can lead to functional changes beyond hair growth effects.
Article
Medicine, Research & Experimental
Xiaoe Lang, Mei Xue, Xiaocui Zang, Fengchun Wu, Meihong Xiu, Xiangyang Zhang
Summary: This study aimed to examine the efficacy, safety, and tolerability of low-dose risperidone combined with sertraline in reducing serious adverse effects in first-episode and medication-naive schizophrenia patients. The results showed that the combination of low-dose risperidone and sertraline was more effective in reducing psychotic symptoms and improving psychosocial functioning, with significantly fewer adverse effects.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Article
Pharmacology & Pharmacy
Liang Zhu, Guanjin Wu, Weiwei Heng, Xuefeng Zang
Summary: In the treatment of Alzheimer's Disease, olanzapine, aripiprazole, and risperidone all showed effectiveness, but aripiprazole demonstrated better safety and fewer adverse reactions, making it more suitable for elderly patients.
PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES
(2021)
Article
Clinical Neurology
Preeya J. Patel, Christian Weidenfeller, Andrew P. Jones, Jens Nilsson, Jay Hsu
Summary: The study evaluated the long-term effects of lurasidone in patients with schizophrenia through post hoc analysis of a DB active control trial and an OLE study. Lurasidone was found to be generally well tolerated and effective in clinically stable schizophrenia patients over the long term, with minimal changes in metabolic variables and prolactin levels compared to risperidone. Patients switching from risperidone to lurasidone also experienced improvements in metabolic parameters and prolactin levels.
NEUROLOGY AND THERAPY
(2021)